332 related articles for article (PubMed ID: 30765202)
41. IL-17: a new actor in IFN-driven systemic autoimmune diseases.
Ambrosi A; Espinosa A; Wahren-Herlenius M
Eur J Immunol; 2012 Sep; 42(9):2274-84. PubMed ID: 22949326
[TBL] [Abstract][Full Text] [Related]
42. Interleukin (IL-6) Immunotherapy.
Tanaka T; Narazaki M; Kishimoto T
Cold Spring Harb Perspect Biol; 2018 Aug; 10(8):. PubMed ID: 28778870
[TBL] [Abstract][Full Text] [Related]
43. IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases.
Beringer A; Miossec P
Autoimmun Rev; 2018 Dec; 17(12):1176-1185. PubMed ID: 30321671
[TBL] [Abstract][Full Text] [Related]
44. [Multiple sclerosis and other autoimmune diseases].
Belniak E; Stelmasiak Z; Papuć E
Neurol Neurochir Pol; 2007; 41(3):259-66. PubMed ID: 17629820
[TBL] [Abstract][Full Text] [Related]
45. Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis.
Pepple KL; Lin P
Ophthalmology; 2018 Dec; 125(12):1977-1983. PubMed ID: 30458922
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic benefits of regulating inflammation in autoimmunity.
Nikoopour E; Schwartz JA; Singh B
Inflamm Allergy Drug Targets; 2008 Sep; 7(3):203-10. PubMed ID: 18782028
[TBL] [Abstract][Full Text] [Related]
47. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model.
Zhang Y; Ren G; Guo M; Ye X; Zhao J; Xu L; Qi J; Kan F; Liu M; Li D
Int Immunopharmacol; 2013 Feb; 15(2):199-205. PubMed ID: 23280345
[TBL] [Abstract][Full Text] [Related]
48. Immunotherapy in autoimmune diseases.
Fong KY
Ann Acad Med Singap; 2002 Nov; 31(6):702-6. PubMed ID: 12520821
[TBL] [Abstract][Full Text] [Related]
49. Targeting IL-23 in human diseases.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Targets; 2010 Jul; 14(7):759-74. PubMed ID: 20536413
[TBL] [Abstract][Full Text] [Related]
50. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis.
Rogier R; Ederveen THA; Boekhorst J; Wopereis H; Scher JU; Manasson J; Frambach SJCM; Knol J; Garssen J; van der Kraan PM; Koenders MI; van den Berg WB; van Hijum SAFT; Abdollahi-Roodsaz S
Microbiome; 2017 Jun; 5(1):63. PubMed ID: 28645307
[TBL] [Abstract][Full Text] [Related]
51. The IL-17 pathway as a major therapeutic target in autoimmune diseases.
Hu Y; Shen F; Crellin NK; Ouyang W
Ann N Y Acad Sci; 2011 Jan; 1217():60-76. PubMed ID: 21155836
[TBL] [Abstract][Full Text] [Related]
52. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.
Lyman M; Lieuw V; Richardson R; Timmer A; Stewart C; Granger S; Woods R; Silacci M; Grabulovski D; Newman R
J Biol Chem; 2018 Jun; 293(24):9326-9334. PubMed ID: 29678878
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
54. Emerging role of IL-35 in inflammatory autoimmune diseases.
Su LC; Liu XY; Huang AF; Xu WD
Autoimmun Rev; 2018 Jul; 17(7):665-673. PubMed ID: 29729445
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-25: key regulator of inflammatory and autoimmune diseases.
Saadoun D; Terrier B; Cacoub P
Curr Pharm Des; 2011 Nov; 17(34):3781-5. PubMed ID: 22103849
[TBL] [Abstract][Full Text] [Related]
56. IL-6 in autoimmune disease and chronic inflammatory proliferative disease.
Ishihara K; Hirano T
Cytokine Growth Factor Rev; 2002; 13(4-5):357-68. PubMed ID: 12220549
[TBL] [Abstract][Full Text] [Related]
57. Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective.
Zwicky P; Unger S; Becher B
J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31727781
[TBL] [Abstract][Full Text] [Related]
58. Unexpected alliance between syndecan-1 and innate-like T cells to protect host from autoimmune effects of interleukin-17.
Jaiswal AK; Sadasivam M; Hamad ARA
World J Diabetes; 2018 Dec; 9(12):220-225. PubMed ID: 30588283
[TBL] [Abstract][Full Text] [Related]
59. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
60. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
Narazaki M; Tanaka T; Kishimoto T
Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
